On January 15, Soumit Roy of JonesTrading reiterated a Buy rating on Nuvation Bio Inc. (NYSE:NUVB) and increased the price target from $10 to $12. Two days earlier, on January 13, Gregory Renza from Truist Financial also maintained a Buy rating on the stock, though no specific price target was provided.
Roy's positive outlook is tied to upcoming data from a study of Safusidenib, an IDH1 inhibitor for post-surgery patients. He expects the data by year-end and has raised the estimated success probability of Safusidenib from 30% to 50%. The analyst now anticipates an accelerated approval, with a potential launch in 2029 instead of 2030.
Also on January 13, H.C. Wainwright reduced its price target for Nuvation Bio from $18 to $17 while keeping a Buy rating. The firm cited IBTROZI's fiscal fourth-quarter 2025 sales of $15.7 million, which fell short of its $16.4 million expectation but aligned with a general consensus of $15.5 million. Consequently, H.C. Wainwright lowered its 2026 sales forecast to $163.2 million from $169.6 million.
Nuvation Bio is a biopharmaceutical company developing new oncology therapies.